Novartis Fends Off US Fingolimod Competition – For Now

No Gilenya Generics Expected ‘For At Least The Next Two Years’ In US, Originator Says

 
• By David Wallace
  
Years 2023, 2024, 2025, 2026
Novartis expects US protection for Gilenya to stretch years into the future • Source: Oakozhan / Alamy Stock Photo
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Legal & IP

More from Generics Bulletin